Laval, Canada

Francois Lepine

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Longueuil, CA (2014)
  • Laval, CA (2014 - 2023)

Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Francois Lepine

Introduction

Francois Lepine is a notable inventor based in Laval, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating infections. With a total of three patents to his name, Lepine's work is recognized for its potential impact on healthcare.

Latest Patents

Francois Lepine's latest patents include innovative compounds designed to combat bacterial infections. One of his patents focuses on broad-spectrum antivirulence and anti-persistence compounds. This application provides malonamide compounds and their derivatives, which are useful for treating acute, chronic, and relapsing infections. Additionally, he has developed methods for identifying candidate compounds that can reduce bacterial virulence, which is crucial for advancing treatment options for pathogenic infections.

Career Highlights

Throughout his career, Lepine has worked with esteemed organizations such as The General Hospital Corporation and the Institut National De La Recherche Scientifique. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Francois Lepine has collaborated with notable colleagues, including Laurence G Rahme and Melissa Starkey. These partnerships have enhanced his research and development efforts, leading to significant advancements in the treatment of infections.

Conclusion

Francois Lepine's innovative work in the pharmaceutical field demonstrates his commitment to improving healthcare through his inventions. His patents and collaborations reflect a dedication to addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…